April 2023 Top Biopharma Deal: DualityBio development and commercialization deal with BioNTech for DB-1303 and DB-1311 for cancer

May 2, 2023 | Deal of the Month

April 2023 Top Biopharma Deal Upfront
DualityBio development and commercialization deal with BioNTech for DB-1303 and DB-1311

Highlighted Deal Financial Comps

Date Announced:

April 3, 2023

Total Deal Value:

$1.67B

Upfront Cash:

$170M

Upfront Equity:

n/a

Option Payments:

n/a

Total Milestones:

Up to $1.5B in development, regulatory, and sales milestone payments.

Royalties:

Single-digit to double-digit tiered royalties.

Cost & Profit Split:

DualityBio retains a co-development/co-promotion cost and profit/loss sharing option for DB-1311 in the U.S. market.

Deal Synopsis

The Asset:

DB-1303, a topoisomerase-1 inhibitor-based ADC, and DB-1311 for the treatment of human cancers.

Deal Structure:

Dev and Commercial License

Partnership Features:

Co-Development, Shared Dev Cost , Co-Promotion, Shared Promotion Cost , Options to Add Products, TAs, and/or Territories

Deal Details:

    • DualityBio granted BioNTech exclusive, worldwide rights, excluding China, Hong Kong, and Macau, to develop and commercialize DB-1303, a topoisomerase-1 inhibitor-based ADC, and DB-1311 for the treatment of human cancers.
    • DualityBio has the option to co-develop and co-promote DB-1311 in the U.S. with cost and profit/loss sharing.
    • DualityBio will receive $170M up front and is eligible for up $1.5B in development, regulatory, and sales milestones, plus single-digit to double-digit tiered royalties.

Last Month:

Congrats to DualityBio and BioNTech for landing DealForma’s April 2023 Top Biopharma Deal. Last month’s Deal of the Month was OncoC4 – BioNTech for ONC-392. Read about it here.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.

We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.

21,135

Licensing Deals

21,479

Funding Rounds

4,145

M&A

34,717

Company Profiles

5,766

Other Deals

26,805

Drug Sales Figures

All of this by stage, disease indication, modality, target...

More Research by DealForma

Neurology Venture Activity Through Q2 2023

Neurology Venture Activity Through Q2 2023

Quarterly venture investment activity into neurology focused biopharma companies is back to pre-2020 level. This is no surprise given the investment slowdowns across all therapy area and broader life sciences. The drop seems to have stabilized however, and emerging...